Who is sponsoring NCT00384033?

NCT00384033 is sponsored by Pfizer.

What condition does NCT00384033 study?

NCT00384033 studies Depressive Disorder, Major.

What drugs are being tested in NCT00384033?

Interventions: Desvenlafaxine Succinate Sustained-Release (DVS SR), Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day.

What is the status of NCT00384033?

NCT00384033 is currently COMPLETED.

Last reviewed 2012-02-09 · How we verify

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder

NCT00384033 Phase 3 COMPLETED Results posted

The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.

Details

Lead sponsor	Pfizer
Phase	Phase 3
Status	COMPLETED
Enrolment	638
Start date	2006-09
Completion	2007-09

Conditions

Depressive Disorder, Major

Interventions

Desvenlafaxine Succinate Sustained-Release (DVS SR)
Desvenlafaxine Succinate Sustained-Release (DVS SR)
Placebo
Duloxetine 60 mg/day

Primary outcomes

Change From Baseline in HAM-D17 Total Score at Week 8 or Final On-therapy (FOT) Evaluation — Baseline and Week 8 or FOT
HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0 = none/absent and 4 = most severe, for a maximum total score of 50.

Countries

United States